



Attorney Ref #: 384A PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Clackson
Serial No.: 09/807,576
Filed : April 13, 2001
For : *Materials and Methods Involving
Conditional Aggregation Domains*

Art Unit: 1632

Examiner: Baker, Anne Marie

U.S. Patents and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

July 17, 2002

Response to Office Communication

This letter is in response to the Office Communication mailed July 9, 2002. The deadline for responding to this Communication is August 8, 2002. Accordingly this response should be deemed timely filed.

Amendment

Please amend the specification as indicated in Attachment A and B to insert Sequence ID numbers. The applicants have reviewed the specification and figures for sequence disclosures and have amended the specification to include SEQ ID numbers in the required positions. These amendments do not change the meaning of the disclosure, whether by removal of any of the disclosure or by introduction of any new matter. A clean version of the amended portions of the specification is provided as Attachment A followed by a marked version as Attachment B.

Furthermore, applicants have compared the amended specification containing SEQ ID numbers and their corresponding sequences with the previously submitted paper and CRF Sequence Listing. All disclosed sequences are contained in proper order in the previously submitted Sequence Listing. Accordingly, and as per paper 7, a new CRF Sequence Listing is not necessary. In accordance with 37 CFR §1.821(a), I hereby state that the sequences contained in the previously submitted Sequence Listing are supported in the application as amended.

A paper copy of the Sequence Listing was submitted to the PTO on 1/28/02. Another copy is provided as Attachment C. Please insert it into the application after page 56, just before the claims.

No additional costs are believed to be due in connection with this amendment. However, should any such fees be due, charge any deficiency or credit any overpayment to our Deposit Account No. 01-2315. A duplicate copy of this letter is enclosed. If there are any questions about this request, the Examiner is invited to call the undersigned attorney at the number provided.

Respectfully submitted,

David L. Bernstein

David L. Bernstein, Reg No. 31,235
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Telephone: 617-494-0400 Ext. 266
Facsimile: 617-494-0208

I hereby certify that this paper is being deposited with the United States Postal Service First Class Mail on the date indicated below and is addressed to the U.S. Patents & Trademark Office; Box Sequence, PO Box 2327; Arlington, VA 22202.

Date July 17, 2002 Signed

Sue Wilson
Sue Wilson

1632
#8a
JUL 24 2002
TECH CENTER 1600/2900
RECEIVED

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 44 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The specification and/or figures must be amended to identify all disclosed sequences by their sequence identifier (i.e., SEQ ID NO), in accordance with 37 CFR 1.821(d). Since the specification and/or figures disclose sequences that are not identified by their sequence identifiers, it is unclear if all disclosed sequences are included in the CRF copy of the sequence listing. A substitute CRF copy of the Sequence Listing is required **only** if the unidentified sequences are not already included in the CRF Sequence Listing.

Applicant Must Provide:

- ☒ An **substitute** computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An **initial** paper copy of the "Sequence Listing", as well as an **amendment** directing its entry into the **specification**.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED

JUL 24 2002

TECH CENTER 1600/2900